Atom

🧪 Scientists just grew a human oesophagus in a lab. And it works. Researchers at Great Ormond Street Hospital and University College London have created the first lab-grown oesophagus that can fully replace a section of the organ, restoring normal swallowing function, without the patient needing immunosuppression. Let that sink in. No rejection drugs. No donor waiting list. Grown tissue that the body simply accepts. For children born with oesophageal conditions, this could be life-changing. For the broader field of regenerative medicine, it's a landmark proof of concept. We're entering an era where the answer to organ failure might not be "find a donor" but "grow one." The lab is becoming the most exciting place on the planet right now. #RegenerativeMedicine #MedicalBreakthrough #Innovation #HealthTech #GreatOrmondStreet #UCL

🐔 What if the future of medicine came from a chicken egg? A US biotech startup is doing exactly that, using genetically modified chickens to turn their eggs into factories for therapeutic proteins used to treat cancer and autoimmune disorders. No massive fermentation tanks. No complex bioreactors. Just eggs. The implications are staggering. Protein-based drugs are among the most expensive medicines to produce and one of the biggest barriers to patient access worldwide. This could change that entirely. We talk a lot about AI and chips dominating the innovation conversation in 2026. But quietly, in a lab somewhere, a chicken just became one of biotech's most promising manufacturing assets. The line between biology and industry is dissolving faster than most people realise. #Biotech #Innovation #HealthcareInnovation #DrugDiscovery #Startups

Brutal truth: Building the tech is the easy part. Scaling it is where most startups die. Startups don’t break in the lab. They break when the product meets the real world: - Manufacturing eats margins - Compliance kills timelines - Early design decisions quietly block entire markets later Most teams only realise this when it’s already too late To solve this, Bosch is opening up its industrial and engineering capabilities to startups through a model called “industrialisation as a service” And we’re helping identify a small number of companies that fit What you get: - Direct access to Bosch engineering and manufacturing - Support turning your product into something scalable - Global capabilities without building them yourself Who they want: - Series A+ - Real technology - Clear path to scaling Important: This is NOT an accelerator. This is NOT investment. This is a partnership opportunity designed to help startups actually scale their product. We’re only putting forward a small number of startups If you’re building in hardware, deeptech, IoT, or anything that has to exist outside a laptop and you’re hitting that wall. Comment “Bosch” and we’ll share more or help you get in front of the right team

In 1938, we invented "forever." In 2026, we finally figured out how to end it. Roy Plunkett accidentally created Teflon while trying to build a better fridge. It was a miracle material until we realized the chemical bond that made it unbreakable meant it never left our bloodstreams. For 80 years, engineers filed IP to create PFAS. Now, the narrative has flipped - they’re racing to destroy it. From Veolia's mineralization tech to startups using nanoporous catalysts, the new wave of IP isn't just filtering water, it’s ripping the molecule apart. Sometimes, the most valuable innovation isn't the one that builds the future it's the one that cleans up the last "miracle." #PFAS #DeepTech #Sustainability #Innovation #Atom

The most valuable materials in the world don't exist yet. But they're already owned. From aerogels lighter than air to metamaterials that bend light backwards, none of these can be manufactured at scale today. But all of the "Materials of 2050" have already been filed, claimed, and assigned to someone. The IP race isn't running alongside the technology race. It's running decades ahead of it. By the time a factory can produce these materials, the legal architecture around them will already be settled. We've been mapping the distance between what's patented and what's currently buildable at Atom since our inception because that's where the market of 2040 is being decided. The question isn't who's building the future, it's who already owns it. #DeepTech #MaterialsScience #IPStrategy #FutureTech #AtomGroupAI #AtomAI #Patents #Innovation

The machine that killed the factory didn't make a sound. It ran perfectly… until it didn’t. That failure was audible 3 weeks earlier, but only to the right sensor. Sensors that detect stress fractures, bearing degradation and pressure anomalies weeks before a technician can, already exist. This isn't emerging technology; it's deployed IP already inside the facilities of companies that decided the cost of knowing was lower than the cost of finding out the hard way. The average unplanned downtime event costs $260,000 per hour. And the average company still finds out from a technician standing next to something that just stopped. Atom maps the patents that determine who’s indispensable on the factory floor in 2030. Which side of that line are you on? #Industry40 #SmartManufacturing #PredictiveMaintenance #AI #AtomGroupAI

In 2016, researchers found a bacteria that (in just 60 years) had evolved naturally in a Japanese recycling facility to eat pure plastic as food. The most elegant waste solution isn't a machine. It's a protein, Ideonella sakaiensis, which produces a unique enzyme (PETase) that breaks down plastic into its basic building blocks. This accidental discovery has since triggered hundreds of patents: engineered enzyme variants, protein cocktails, closed-loop systems that break PET plastic back to virgin-grade monomers… indefinitely. The blueprints exist. So, is the barrier still technical? Or has it become political? At Atom, we are indexing the patents that move this from a biological fluke to an industrial standard. #Biotech #CircularEconomy #Sustainability #AtomGroupAI #EnzymeEngineering  #AtomAI #Patents #Innovation

Even in Sahara, the air is a water reservoir. We just haven’t had the sponge to soak it up. Until now. We are monitoring a breakthrough in Metal-Organic Frameworks (MOFs), nanoscopic structures with the surface area of a football field in a single gram. Recent patents describe MOF systems that pull liters of drinkable water from 10% humidity using nothing but ambient sunlight. No pumps, no grid, no wells. Just air. For desert economies, remote mining sites, and off-grid communities, this could redefine water infrastructure entirely. At Atom, we identify the strongest yield-to-cost potential and the IP most likely to move from lab breakthrough to real-world deployment. Because when water can be harvested from air, the real question becomes: who owns the technology that makes it possible? #WaterSecurity #Sustainability #ClimateTech #Nanotechnology #CleanWater #ResourceInnovation #GreenTech #AtomAI #Patents #Innovation

An energy executive, a catalyst chemist and a patent lawyer are arguing over the same thing… one Atom. Researchers are now building single-atom catalysts: materials where individual atoms perform industrial reactions like hydrogen production and carbon capture. Just one Atom doing the entire work of what used to require clusters of rare metals. The result? Higher efficiency, lower material use, and dramatically different economics for energy and chemical processes. The science is advancing fast, and so is the IP landscape around atomic-scale catalyst design. We chose our name deliberately: Atom isn’t just a unit of matter, it is how we map the patents that control technologies designed at atomic scale. Because the next industrial breakthrough may not be about building bigger, but about the better control of one single Atom. #DeepTech #AdvancedMaterials #Catalysis #Patents #EnergyTransition #AtomAI #Patents #Innovation

25% of vaccines reach their destination degraded. Not because they were made poorly, but because a fridge failed. For decades, global health has depended on one expensive, fragile system: the Cold Chain, a multi-billion dollar logistical nightmare of dry ice and sensors. Trucks, warehouses, and clinics are all working perfectly to keep vaccines chilled. At Atom, we’re tracking an increase in silk fibroin and sugar-glass encapsulation technologies that can stabilise life-saving proteins at 40°C for months. No refrigeration. No fragile logistics chain. We’ve been mapping the patents that could make the Cold Chain obsolete. So what happens to the global logistics market when the world’s most sensitive cargo no longer needs a plug? #SupplyChainLogistics #DeepTech #ColdChain #PharmaTech #InnovationStrategy #Biotechnology #AtomAI #Patents #Innovation